Literature DB >> 1739771

[Cervical lymph node metastases. The sonographic demonstration of malignancy].

H J Steinkamp1, N Hosten, R Langer, F Mathe, C Ehritt, R Felix.   

Abstract

The value of sonography for demonstrating cervical lymph node metastases has been studied, using longitudinal and transverse measurements as criteria for malignancy. A transverse/longitudinal quotient greater than 2 indicates the presence of metastases with a 96% assurance. Using only longitudinal measurements lymph node metastases can be excluded with only a 36% assurance. The sensitivity of both methods also differs (95% for the maximal transverse quotient as against 90% for longitudinal measurements). The use of the maximal transverse quotient increases specificity from 36 to 96%. This gives sonography an accuracy of 95%.

Entities:  

Mesh:

Year:  1992        PMID: 1739771     DOI: 10.1055/s-2008-1032852

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  4 in total

1.  Evaluation and development of a predictive model for ultrasound-guided investigation of neck metastases.

Authors:  Jens Eduard Meyer; Armin Steffen; Martin Bienemann; Juergen Hedderich; Ulrike Schulz; Martin Laudien; Joachim Quetz; Barbara Wollenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-06       Impact factor: 2.503

2.  [Sonography of enlarged lymph nodes: Pathogenetic categorization using contrast enhanced power Doppler sonography].

Authors:  B M Stoeckelhuber; M Wiesmann; S A Berg; M Tronnier; M Stoeckelhuber; S Krueger; J Gellissen; C U Bergmann-Koester
Journal:  Hautarzt       Date:  2006-07       Impact factor: 0.751

3.  Recurrent cervical lymphadenopathy: differential diagnosis with color-duplex sonography.

Authors:  H J Steinkamp; J Mäurer; M Cornehl; D Knöbber; H Hettwer; R Felix
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

4.  Vascular patterns in reactive and malignant lymphadenopathy.

Authors:  A Tschammler; H Wirkner; G Ott; D Hahn
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.